Abstracts tagged "rheumatoid arthritis"

Abstract Number: 991 • 2019 ACR/ARP Annual Meeting
Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides
Matthew McElwee¹, Thamotharampillai Dileepan ¹ and Marc Jenkins ¹, ¹University of Minnesota, Minneapolis, MN
Background/Purpose: Seropositive rheumatoid arthritis (RA) is a T-cell mediated disease that is characterized by the presence of antibodies to proteins that have undergone the post-translational…
Abstract Number: 1411 • 2019 ACR/ARP Annual Meeting
Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy
Yushiro Endo¹, Tomohiro Koga ¹, Shin-ya Kawashiri ¹, Ayako Nishino ¹, Momoko Okamoto ¹, Shimpei Morimoto ², Sosuke Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Takashi Igawa ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ³, Yukitaka Ueki ⁴, Tamami Yoshitama ⁵, Nobutaka Eiraku ⁶, Naoki Matsuoka ⁷, Akitomo Okada ⁸, Keita Fujikawa ⁹, Hiroaki Hamada ¹⁰, Tomomi Tsuru ¹¹, Shuji Nagano ¹², Yojiro Arinobu ¹³, Toshihiko Hidaka ¹⁴, Yoshifumi Tada ¹⁵ and Atsushi Kawakami ¹⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Nagasaki University Hospital Clinical Research Centre, Nagasaki, Japan, ³Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁴Sasebo Chuo Hospital Rheumatic and Collagen Disease Center, Sasebo, Japan, ⁵Yoshitama Clinic for Rheumatic Diseases, Kirishima, Japan, ⁶Eiraku Clinic for Rheumatic Diseases, Kagoshima, Japan, ⁷Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ⁸Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁹JCHO Isahaya General Hospital Department of Rheumatology, Isahaya, Japan, ¹⁰Miyazaki University Hospital, Miyazaki, Japan, ¹¹PS clinic, Fukuoka, Japan, ¹²Aso Iizuka Hospital, Iizuka, Japan, ¹³Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, ¹⁴Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ¹⁵Saga University Hospital, Saga, Japan, ¹⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Rheumatoid arthritis (RA) occasionally overlaps Sjogren’s syndrome (SS), and RA patients with secondary SS have a higher disease activity of RA and worse joint…
Abstract Number: 2009 • 2019 ACR/ARP Annual Meeting
Biomarkers Identified by Serum Inflammatory Profile Analysis to Predict Biologic Treatment Response in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Nuria Barbarroja ², Carlos Perez-Sanchez ³, Pilar Font ⁴, Alejandro Ibañez-Costa ¹, Maria Luque-Tevar ¹, Alejandra Patiño-Trives ¹, Ivan Arias de la Rosa ⁴, Maria del Carmen Abalos-Aguilera ¹, Rafaela Ortega ¹, Alejandro Escudero ⁵, Laura Pérez-Sanchez ⁶, Jerusalem Calvo-Gutierrez ¹, Rocío Segura-Ruiz ⁷, Carlos Rodriguez Escalera ⁸, Dolores Ruiz-Montesinos ⁹, Carmen Romero Barco ¹⁰, N. Mena-Vazquez ¹¹, Julia Uceda Montañez ¹², Mª Dolores Toledo Coello ¹³, M Angeles Aguirre ¹⁴ and Eduardo Collantes-Estevez ⁴, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁷Reina Sofia University Hospital/IMIBIC, Córdoba, Spain, ⁸Hospital Universitario de Jaén, Jaen, Spain, ⁹Hospital Virgen Macarena, Sevilla, ¹⁰Hospital Marítimo de Torremolinos, Málaga, Málaga, Spain, ¹¹HU Malaga., Malaga, ¹²Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, ¹³Hospital Universitario de Jerez de la Frontera, Cádiz, Cádiz, Spain, ¹⁴IMIBIC/Reina Sofia Hospital/University of Cordoba,, Córdoba, Spain
Background/Purpose: Biologic disease modifying antirheumatic drugs (b-DMARDs) have revolutionized the management of Rheumatoid Arthritis (RA). Despite this success, a high percentage of the patients undergoing…
Abstract Number: 2401 • 2019 ACR/ARP Annual Meeting
Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate
Thierry Dervieux¹, Joel Kremer ², Kelley Brady ¹, Chihiro Takahashi ³, Tsutomu Takeuchi ⁴ and Yuko Kaneko ⁵, ¹Exagen, Vista, CA, ²Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, ³Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Keio University Hospital Division of Rheumatology, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is an anti-folate prodrug activated to MTX polyglutamates (MTXPGs). Japanese Rheumatoid Arthritis (RA) patients are thought to have heightened sensitivity to MTX…
Abstract Number: 508 • 2019 ACR/ARP Annual Meeting
Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Sakae Tanaka ³, Atsushi Kawakami ⁴, Yeong-Wook Song ⁵, Yi-Hsing Chen ⁶, Mitsuhiro Rokuda ⁷, Hiroyuki Izutsu ⁷, Satoshi Ushijima ⁷, Yuichiro Kaneko ⁷, Yoshihiro Nakashima ⁷, Teruaki Shiomi ⁷ and Emi Yamada ⁷, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³University of Tokyo, Tokyo, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Seoul National University Hospital, Seoul, Republic of Korea, ⁶Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁷Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, demonstrated efficacy and an acceptable safety profile in a Phase 2b study (RAJ1 study, NCT01649999) and…
Abstract Number: 547 • 2019 ACR/ARP Annual Meeting
Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis
Charles Peterfy¹, Mark Genovese ², In-Ho Song ³, Alan Friedman ⁴, Stephen Hall ⁵, Eduardo Mysler ⁶, Patrick Durez ⁷, Xenofon Baraliakos ⁸, Jose Jeffrey Enejosa ⁹, Tim Shaw ⁴, Yihan Li ⁹, Su Chen ⁴ and Vibeke Strand ¹⁰, ¹Spire Sciences Inc, Boca Raton, ²Stanford University, Stanford, CA, ³AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁴AbbVie Inc., North Chicago, ⁵Monash University and Emeritus Research, Melbourne, Australia, ⁶Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁷Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, ⁸Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁹AbbVie Inc., North Chicago, IL, ¹⁰Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Long‑term prevention of structural joint damage is a key treatment goal in the management of RA1. Upadacitinib (UPA), a JAK1-selective inhibitor, inhibited the progression…
Abstract Number: 995 • 2019 ACR/ARP Annual Meeting
Inhibition of Endoplasmic Reticulum Stress Using 4-phenylbutyric Acid Ameliorates the Severity of Collagen-induced Arthritis in Mice via Attenuation of Proliferation and Inflammatory Responses of Synovial Fibroblasts
Wan-Hee Yoo¹, Yunjung Choi ², Eun-gyeong Lee ², Chang-hoon Lee ³ and Myeung-Su Lee ³, ¹Department of Internal Medicine, Chonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University-Biomedical, Research Institute of Chonbuk National University Hospital, Jeonju, Korea, JeonJu, Republic of Korea, ²Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, JeonJu, Republic of Korea, ³Wonkwang University College of Medicine, Iksan, Republic of Korea
Background/Purpose: Several studies have recently revealed the pathological role of endoplasmic reticulum (ER) stress in the pathogenesis of inflammatory diseases. In addition, 4-phenylbutyric acid (4-PBA) was…
Abstract Number: 1423 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Joe Zhuo ⁷, Kuan-Hsiang Gary Huang ⁸, Robert Wong ⁷, Sean Connolly ⁸, Yedid Elbez ⁹ and Roy Fleischmann ¹⁰, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Excelya, Boulogne-Billancourt, France, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Early biologic use can improve long-term control of RA, and early use of abatacept (ABA) + MTX has demonstrated sustained improvements in selected patient-reported…
Abstract Number: 2016 • 2019 ACR/ARP Annual Meeting
Expression of Peptidyl-arginine Deiminases in Peripheral Blood Neutrophils and Its Association with Single Nucleotide Variants in Patients with Rheumatoid Arthritis
Masayoshi Harigai¹, Ryoko Sakai ², Takahiko Sugihara ³ and Akihito Ishigami ⁴, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Tokyo Medical and Dental University, Tokyo, Japan, ⁴Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
Background/Purpose: Peptidyl-arginine deiminases (PADIs) are enriched in neutrophils and considered to be responsible for citrullination of proteins in vivo. Autoantibody against citrullinated proteins are frequently…
Abstract Number: 2403 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³ and Daisuke Kato ³, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in studies of Japanese, Korean and Taiwanese patients with RA. This analysis of…
Abstract Number: 628 • 2018 ACR/ARHP Annual Meeting
Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database
Elliot Hepworth¹, Mohammad Movahedi², Emmanouil Rampakakis³, Reza Mirza¹, Arthur Lau⁴, Angela Cesta⁵, Janet E. Pope⁶ and Claire Bombardier⁷, ¹Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴50 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next…
Abstract Number: 2898 • 2018 ACR/ARHP Annual Meeting
Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)
Paula Fortea-Gordo¹, Laura Nuño², Alejandro Villalba², Diana Peiteado³, Irene Monjo⁴, Paloma Sanchez-Mateos⁵, Amaya Puig-Kröger⁶, Alejandro Balsa¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Immunology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: A novel population of CD4+ T cells with B cell helping capacity has been described in the synovial tissues and peripheral blood of seropositive…
Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan
Song-Chou Hsieh¹, Yi-Hsing Chen², Wei-Sheng Chen³, Wen-Chan Tsai⁴, Jui-Chieh Hu⁵, Hsiang-Cheng Chen⁶, Jack Mardekian⁷ and Chacun Lai⁸, ¹National Taiwan University Hospital, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung City, Taiwan, ³Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, ⁷Pfizer Global Biometrics & Data Management, NY, NY, ⁸Pfizer PFE Limited, New Taipei, Taiwan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting
Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
Judith Ashouri¹, Lih-Yun Hsu¹, Dmitry Rychkov², Marina Sirota², Lisa Lattanza³, Eric Hansen³, Julie Zikherman¹ and Arthur Weiss¹, ¹Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ³Orthopedic Surgery, University of California, San Francisco, San Francisco, CA
Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting
Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
Caitrin Coffey¹, Michael Richter¹, Cynthia S. Crowson², Matthew J. Koster³, Kenneth J. Warrington⁴ and Ashima Makol³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].